ANVS 8-K
Annovis Bio, Inc. (ANVS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date
of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices, and Zip Code)
(
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name
of each exchange on which registered |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On August 14, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits |
| Exhibit Number | Description | |
| 99 | Press Release Dated August 14, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANNOVIS BIO, INC. | ||
| Date: August 14, 2026 | ||
| By: | /s/ Maria Maccecchini | |
| Name: Maria Maccecchini | ||
| Title: President and Chief Executive Officer | ||
Exhibit 99.1
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
| · | Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding original projections. |
| · | Parkinson’s disease (PD) open-label extension (OLE) study has enrolled 266 patients with full enrollment projected in Q4 2026. |
| · | Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT. |
Malvern, PA, August 14, 2026 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.
“Our company witnessed major clinical strides during the second quarter,” said Maria Maccecchini, Ph.D., President and CEO of Annovis. “We reached an important milestone – full enrollment of our pivotal Phase 3 study in early AD – having recruited 850 patients. This number tells us how urgently patients and families need new options and underscores their faith in our approach to treating AD. We also plan to continue the ongoing study with an open-label extension (OLE) so AD patients can continue buntanetap treatment after finishing the trial. With topline data on track for early 2027, our team has already begun preparing for regulatory submission so that we are ready to move once the results are in hand.”
Clinical highlights
Alzheimer’s disease – pivotal Phase 3 trial
| · | Enrollment: The trial is fully enrolled with 850 patients, exceeding the original target enrollment number of 760 patients. |
| · | Patients: The pivotal Phase 3 AD trial includes patients diagnosed with early AD (MMSE 20-28) who are also positive for plasma pTau217 biomarker, confirming the presence of amyloid and tau pathology in the brain. |
| · | Study design: The study measures cognition (ADAS-Cog13) and function (ADCS-iADL) as co-primary endpoints, supported by volumetric MRI, pTau217, and other biomarkers to evaluate changes in disease pathology. The study is designed to test both symptomatic (6 months) and disease-modifying (18 months) effects of buntanetap. |
| · | Timeline: The Company plans a database lock for the 6-month analysis in Q1 2027, with the top-line symptomatic data readout anticipated in the same quarter. The disease-modifying data readout is expected a year later. |
Alzheimer’s disease – OLE study
| · | Start: The AD OLE study is expected to initiate in October 2026. |
| · | Aim and patients: The AD OLE study will allow patients who are currently in the pivotal Phase 3 trial to receive buntanetap after completing their 18-month treatment period. Patients from both arms – buntanetap and placebo – will be allowed to join. The initiation of the AD OLE is timed to coincide with the first patient finishing their 18-month treatment, ensuring seamless transition into the extension study. The AD OLE will also be open to participants from Annovis’ prior AD clinical trials. |
Parkinson’s disease – OLE study
| · | Enrollment: The study has so far enrolled 266 patients toward its estimated enrollment goal of 500. It accepts participants who were in prior Annovis’ clinical trials as well as new patients who have deep brain stimulation (DBS). |
| · | Site activation: 26 clinical sites have been activated across the US. |
| · | Study design: The PD OLE study is designed to evaluate buntanetap's safety and long-term efficacy over the period of 36 months, supported by NeuroRPM, a real-time digital biomarker that measures core PD symptoms, and a skin biopsy test for alpha-synuclein pathology. |
Corporate highlights
| · | Management: Annovis promoted Cheng Fang, Ph.D., to Chief Scientific Officer (CSO), where she will oversee the clinical execution and scientific advancement of buntanetap as the Company approaches key regulatory milestones. |
Upcoming milestones
| · | Corporate webinar: Annovis will host a corporate update webinar on Wednesday, September 2, 2026, at 4:00 pm EDT. To participate, please register using the following link: Annovis Webinar - Corporate Update |
| · | Questions: Participants are encouraged to submit questions in advance to [email protected] |
Financial results
| · | Annovis’ cash and cash equivalents totaled $18.7 million as of June 30, 2026, compared to $19.5 million as of December 31, 2025. Annovis had 42.6 million shares of common stock outstanding as of June 30, 2026. |
| · | Research and development expenses for the three months ended June 30, 2026, were $12.0 million compared to $5.2 million for the three months ended June 30, 2025. |
| · | General and administrative expenses for the three months ended June 30, 2026, were $2.4 million compared to $1.1 million for the three months ended June 30, 2025. |
| · | Annovis reported a $0.40 basic and diluted net loss per common share for the three months ended June 30, 2026, compared to a $0.32 basic and diluted net loss per common share for the three months ended June 30, 2025. |
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact
Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor
Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
[email protected]
(Tables to follow)
ANNOVIS BIO, INC.
Balance Sheets
| June 30, | ||||||||
| 2026 | December 31, | |||||||
| (Unaudited) | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 18,728,945 | $ | 19,532,338 | ||||
| Prepaid expenses and other current assets | 3,308,146 | 1,549,287 | ||||||
| Total assets | $ | 22,037,091 | $ | 21,081,625 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,327,138 | $ | 2,590,516 | ||||
| Accrued expenses | 3,031,572 | 1,044,859 | ||||||
| Total current liabilities | 6,358,710 | 3,635,375 | ||||||
| Non-current liabilities: | ||||||||
| Warrant liability | 19,933,000 | 595,000 | ||||||
| Total liabilities | 26,291,710 | 4,230,375 | ||||||
| Commitments and contingencies (Note 6) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding | — | — | ||||||
| Common stock - $0.0001 par value, 70,000,000 shares authorized, 42,606,152 and 27,199,139 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 4,260 | 2,719 | ||||||
| Additional paid-in capital | 191,871,978 | 180,552,190 | ||||||
| Accumulated deficit | (196,130,857 | ) | (163,703,659 | ) | ||||
| Total stockholders’ equity | (4,254,619 | ) | 16,851,250 | |||||
| Total liabilities and stockholders’ equity | $ | 22,037,091 | $ | 21,081,625 | ||||
ANNOVIS BIO, INC.
Statement of Operations
(Unaudited)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 12,007,300 | $ | 5,161,921 | $ | 28,727,663 | $ | 10,173,438 | ||||||||
| General and administrative | 2,370,412 | 1,109,532 | 3,662,232 | 2,380,696 | ||||||||||||
| Total operating expenses | 14,377,712 | 6,271,453 | 32,389,895 | 12,554,134 | ||||||||||||
| Operating loss | (14,377,712 | ) | (6,271,453 | ) | (32,389,895 | ) | (12,554,134 | ) | ||||||||
| Other income: | ||||||||||||||||
| Interest income | 160,233 | 191,395 | 298,033 | 379,007 | ||||||||||||
| Other financing costs (Note 7) | (1,589,336 | ) | — | (1,589,336 | ) | — | ||||||||||
| Change in fair value of warrants (Note 7) | 986,000 | (140,000 | ) | 1,254,000 | 418,000 | |||||||||||
| Total other income, net | (443,103 | ) | 51,395 | (37,303 | ) | 797,007 | ||||||||||
| Net loss | $ | (14,820,815 | ) | $ | (6,220,058 | ) | $ | (32,427,198 | ) | $ | (11,757,127 | ) | ||||
| Net loss per share (Note 9) | ||||||||||||||||
| Basic | $ | (0.40 | ) | $ | (0.32 | ) | $ | (0.99 | ) | $ | (0.64 | ) | ||||
| Diluted | $ | (0.40 | ) | $ | (0.32 | ) | $ | (0.99 | ) | $ | (0.64 | ) | ||||
| Weighted-average number of common shares used in computing net loss per share | ||||||||||||||||
| Basic | 37,518,778 | 19,486,231 | 32,710,046 | 18,464,877 | ||||||||||||
| Diluted | 37,518,778 | 19,486,231 | 32,710,046 | 18,464,877 | ||||||||||||